Fig. 1: The sensitivity of HR-proficient ovarian cancer cell lines to PARP inhibitors and ATO. | Cell Death Discovery

Fig. 1: The sensitivity of HR-proficient ovarian cancer cell lines to PARP inhibitors and ATO.

From: Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors

Fig. 1

A BRCA1/2 and HRD status of selected ovarian cancer cell lines. B–F Drug-response curves of cell viability after PARP inhibitors (niraparib, olaparib, and fluazolepali) and ATO treatment, respectively, in HR-proficient ovarian cancer cells (A2780 (B), CAOV3 (C), OVCAR3 (D), and SKOV3 (E)) measured by CCK8 assay at 72 h. Mean ± SD shown (n = 3 biologically independent replicates per treatment and experiment repeated thrice). IC50 was calculated by GraphPad Prism 9.0 (F).

Back to article page